September 1, 2026

REVISED

Barinthus Biotherapeutics plc – Exchange
ADS CUSIP: 91864C107
ADS ISIN: US91864C1071
ADS Ticker Symbol: BRNS
Ratio (ADS: Underlying Shares): 1: 1

Further to our notice dated August 21, 2026, the effective date has been revised to September 9th.

Barinthus Biotherapeutics plc ("Barinthus") under an Agreement and Plan of Merger will be acquired by Clywedog Therapeutics Holdings, Inc. ("Clywedog"). Under the terms of the scheme of arrangement, shareholders of Barinthus will receive one (1) share of Clywedog for every nine (9) shares of Barinthus. Barinthus American Depositary Share ("ADS") holders will receive 0.11111111 Clywedog shares for every one (1) ADS of Barinthus.

As a result, effective **September 9, 2026** (the "Exchange Date"), Barinthus registered American Depositary Receipt ("ADR") holders will be required on a mandatory basis to surrender their ADRs to BNY Mellon for cancellation and exchange to receive 0.11111111 Clywedog shares (CUSIP 18978T106) for every one (1) Barinthus ADS (CUSIP 91864C107). Holders of Barinthus ADSs in the Direct Registration System or in brokerage accounts will have their Barinthus ADSs automatically exchanged and need not take any action. Only whole Clywedog shares will be distributed. BNY Mellon will attempt to sell any fractional Clywedog shares and distribute the net cash proceeds.

Please note below the timetable for the exchange:

ADR Exchange Date:	**September 9, 2026**
Exchange Ratio:	0.11111111 Clywedog Shares for every 1 Barinthus ADS
Barinthus CUSIP:	91864C107
BRNS Last Day of Trading:	September 8, 2026
Clywedog CUSIP:	18978T106
Cancellation Fee:	$0.00

Consequently, BNY Mellon hereby notifies ADR holders of Barinthus Biotherapeutics plc that the agreement between BNY Mellon and ADR holders will terminate the day on which there are no remaining outstanding ADSs expected to be on September 9, 2026.

BNY Mellon's books will be closed on CUSIP 91864C107 for issuances and cancellations from the close of business August 31, 2026.

To learn more about DRs, please contact DRBrokerSolutions@bnymellon.com or visit our website at adrbny.com.

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued. From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program. BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor. BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY. In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary. In such cases, BNY has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed at https://www.adrbny.com/content/dam/adr/documents/fees-and-disclosures-pdf/drs_foreign_exchange_pricing_disclosure.pdf.

In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or to ensure that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect losses associated with the rate. In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency. In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is the most favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle. BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BNY).